Aperio Group LLC Has $2.32 Million Holdings in ABIOMED, Inc. (ABMD)

Aperio Group LLC grew its position in ABIOMED, Inc. (NASDAQ:ABMD) by 4.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 13,729 shares of the medical equipment provider’s stock after purchasing an additional 531 shares during the quarter. Aperio Group LLC’s holdings in ABIOMED were worth $2,315,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its holdings in ABIOMED by 0.5% in the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 5,947 shares of the medical equipment provider’s stock worth $852,000 after purchasing an additional 32 shares during the last quarter. BB&T Securities LLC grew its holdings in ABIOMED by 1.0% in the second quarter. BB&T Securities LLC now owns 4,154 shares of the medical equipment provider’s stock worth $595,000 after purchasing an additional 43 shares during the last quarter. Teacher Retirement System of Texas grew its holdings in ABIOMED by 1.6% in the second quarter. Teacher Retirement System of Texas now owns 3,294 shares of the medical equipment provider’s stock worth $472,000 after purchasing an additional 51 shares during the last quarter. Capstone Asset Management Co. grew its holdings in ABIOMED by 1.1% in the second quarter. Capstone Asset Management Co. now owns 6,410 shares of the medical equipment provider’s stock worth $919,000 after purchasing an additional 70 shares during the last quarter. Finally, Utah Retirement Systems grew its holdings in ABIOMED by 1.4% in the second quarter. Utah Retirement Systems now owns 7,400 shares of the medical equipment provider’s stock worth $1,060,000 after purchasing an additional 100 shares during the last quarter. 90.46% of the stock is currently owned by institutional investors and hedge funds.



ABIOMED, Inc. (NASDAQ ABMD) opened at $195.21 on Monday. The stock has a market cap of $8,631.43, a price-to-earnings ratio of 125.14, a P/E/G ratio of 2.60 and a beta of 0.23. ABIOMED, Inc. has a 1 year low of $103.53 and a 1 year high of $198.29. The company has a current ratio of 5.84, a quick ratio of 5.20 and a debt-to-equity ratio of 0.02.

ABIOMED (NASDAQ:ABMD) last posted its earnings results on Thursday, October 26th. The medical equipment provider reported $0.54 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.38 by $0.16. The company had revenue of $132.80 million during the quarter, compared to the consensus estimate of $131.18 million. ABIOMED had a net margin of 18.27% and a return on equity of 13.89%. The firm’s quarterly revenue was up 28.9% on a year-over-year basis. During the same period in the previous year, the firm posted $0.20 earnings per share. equities analysts anticipate that ABIOMED, Inc. will post 2.38 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This news story was posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this news story on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this news story can be viewed at https://ledgergazette.com/2017/11/13/aperio-group-llc-has-2-32-million-holdings-in-abiomed-inc-abmd.html.

Several equities analysts have issued reports on the stock. BidaskClub raised shares of ABIOMED from a “hold” rating to a “buy” rating in a report on Thursday, August 10th. SunTrust Banks, Inc. reissued a “buy” rating and set a $195.00 price objective on shares of ABIOMED in a report on Wednesday, November 1st. Jefferies Group LLC boosted their price objective on shares of ABIOMED from $175.00 to $208.00 and gave the company a “buy” rating in a report on Friday, September 29th. Zacks Investment Research raised shares of ABIOMED from a “hold” rating to a “buy” rating and set a $220.00 price objective on the stock in a report on Tuesday, November 7th. Finally, BTIG Research reissued a “hold” rating on shares of ABIOMED in a report on Sunday, October 29th. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $185.38.

In related news, Director Dorothy E. Puhy sold 6,364 shares of the business’s stock in a transaction on Monday, October 30th. The shares were sold at an average price of $179.08, for a total transaction of $1,139,665.12. Following the completion of the transaction, the director now directly owns 39,532 shares in the company, valued at $7,079,390.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Michael G. Howley sold 10,000 shares of the company’s stock in a transaction dated Monday, October 30th. The stock was sold at an average price of $178.64, for a total transaction of $1,786,400.00. Following the completion of the transaction, the vice president now owns 56,757 shares of the company’s stock, valued at approximately $10,139,070.48. The disclosure for this sale can be found here. Insiders have sold 61,646 shares of company stock valued at $10,003,780 over the last 90 days. 7.00% of the stock is currently owned by insiders.

About ABIOMED

ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.

Institutional Ownership by Quarter for ABIOMED (NASDAQ:ABMD)

Receive News & Ratings for ABIOMED Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply